These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 9110651)

  • 1. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
    Valero V
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxoids in combination chemotherapy for metastatic breast cancer.
    Dieras V; Fumoleau P; Bourgeois H; Misset JL; Azli N; Pouillart P
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():47-52. PubMed ID: 8862712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
    Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
    Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Taxoids: effective agents in anthracycline-resistant breast cancer.
    Ravdin PM
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of patients resistant to anthracycline therapy.
    Ravdin PM
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of patients resistant to paclitaxel therapy.
    Valero V
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
    Trudeau ME
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-agent docetaxel (Taxotere) in randomized phase III trials.
    Burris HA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
    van Oosterom AT
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
    Crown J
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
    Ravdin PM
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.